Helix Energy Solutions Group, Inc.Helix Energy Solutions Group, Inc. experienced a significant downturn in the midst of Tuesday’s trading session, driven by disappointing earnings results.
The company’s adjusted earnings of 6 cents per share fell short of market expectations of 10 cents per share. Additionally, quarterly sales amounted to $335.16 million, missing estimates of $315.60 million.
As a result, Helix Energy Solutions shares plummeted by 11% to $9.13 on Tuesday.
Let’s take a closer look at other notable stocks that are making moves during today’s mid-day session.
Stocks Making Gains
- Janux Therapeutics, Inc. saw its shares surge by 145% to $37.00 after announcing updated clinical data for its ongoing programs
- Presto Automation Inc. experienced a remarkable increase of 72% to reach $0.5657
- Viking Therapeutics, Inc. witnessed a substantial rise of 71.2% to $65.88 following positive results from its Phase 2 VENTURE trial
- CXApp Inc. climbed 67% to $2.58
- WeTrade Group, Inc. gained 50% to $3.36
- Hims & Hers Health, Inc. soared by 33.6% to $13.70 after reporting strong fourth-quarter financial performance and issuing optimistic guidance
- Biora Therapeutics, Inc. surged by 32.2% to $1.39
- AdaptHealth Corp. jumped by 29.6% to $9.89 following its fourth-quarter results
- Codexis, Inc. rose by 29% to $4.1283 after securing an exclusive licensing agreement with Roche
- Beam Therapeutics Inc. reported a gain of 26.8% to $45.43 after its fourth-quarter financial report
The Market’s Dance: Winners and Losers
Winners
- Limited NVCR sparked to life, dancing up by 9.5% to $16.31.
- TransMedics Group, Inc. TMDX donned its best moves, gaining 9.5% to $85.14. The company wowed investors with fourth-quarter financial results beyond expectations and a promising forecast, setting the stage for applause.
Losers
- Minerva Neurosciences, Inc. NERV stumbled dramatically, plunging 56.9% to $2.93. The company received a somber note from the FDA, a Complete Response Letter, concerning the New Drug Application for roluperidone in treating schizophrenia’s negative symptoms.
- Infobird Co., Ltd IFBD experienced a dizzying 55.8% drop to $1.2180. The company’s volatile journey took an unexpected turn with delays in its planned reverse stock split causing investors to reel.
- NRx Pharmaceuticals, Inc. NRXP tumbled drastically by 32.7% to $0.2878. The company’s announcement of an underwritten public offering of common stock at $0.30/share, alongside other financial commitments, painted a bleak financial picture, leading to this gloomy descent.
Now Read This: How To Earn $500 A Month From eBay Stock Ahead Of Q4 Earnings Report